A microELISA system for the detection of both anti-HIV-1 and anti-HIV-2 antibodies.
Current anti-HIV-1 screening tests combine an excellent anti-HIV-1 sensitivity with a sensitivity of only 28-93% for anti-HIV-2 positive plasma or serum samples. The reactivity of anti-HIV-2 sera in anti-HIV-1 screening tests is based mainly on the immunological cross-reactivity of the GAG and POL proteins of HIV-1 and HIV-2. We describe here a sandwich immunoassay, in which HIV-1 viral lysate is combined with an HIV-2 ENV synthetic peptide, corresponding to the immunodominant envelope epitope, as the coating antigens on microELISA plates. This immunoassay has a sensitivity of 100% for anti-HIV-1 (128 sera tested) and 100% for anti-HIV-2 (109 sera tested). Assay specificity with fresh human donor sera was 99.9% (2256 sera tested).
Sprengers
E D
ED
Organon Teknika B.V., Screening Systems Research Unit, Boxtel, The Netherlands.
Hellings
J A
JA
Theunissen
H J
HJ
Ten Kortenaar
P B
PB
D004797:Enzyme-Linked Immunosorbent Assay; D015483:HIV Antibodies / Q000032:analysis*; D015497:HIV-1 / Q000276:immunology*; D015498:HIV-2 / Q000276:immunology*; D006801:Humans; D012680:Sensitivity and Specificity
D015483:HIV Antibodies